U.K.-based SkyePharma has completed a Phase III safety study of FlutiformTM, an asthma treatment. Results are consistent with the large safety database already accumulated on the individual constituents fluticasone and formoterol. In August, SkyPharma was dealt a setback when the FDA asked for more data before it would approve the drug. Three more studies are ongoing and the company expects submission of the NDA by the half of 2008.
- see the release for more